<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120999</url>
  </required_header>
  <id_info>
    <org_study_id>21-007425</org_study_id>
    <nct_id>NCT05120999</nct_id>
  </id_info>
  <brief_title>Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring</brief_title>
  <official_title>Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring: A Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to use 2 devices to compare the difference in the amount of&#xD;
      time it takes for each device to register complete muscle relaxation after the muscle&#xD;
      relaxing medication is given. The comparison will be made by using electromyographic (EMG),&#xD;
      such as TetraGraph, and acceloromyographic (AMG), such as TOFScan, monitors at the time of&#xD;
      insertion of breathing tube.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time difference</measure>
    <time_frame>During the initiation of anesthesia period</time_frame>
    <description>Compare time difference from neuromuscular blockade agent administration to neuromuscular blockade onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intubating conditions</measure>
    <time_frame>During the initiation of anesthesia period</time_frame>
    <description>Assess intubating conditions once a complete neuromuscular blockade has been achieved either by TetraGraph or TOFScan measurements</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Dominant hand</arm_group_label>
    <description>Application of either TetraGraph or TOFScan device on dominant hand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Dominant hand</arm_group_label>
    <description>Application of either TetraGraph or TOFScan device on non-dominant hand</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Train of four measurement</intervention_name>
    <description>Use of either TetraGraph or TOFScan to measure the neuromuscular blockade</description>
    <arm_group_label>Dominant hand</arm_group_label>
    <arm_group_label>Non-Dominant hand</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Qualified participants will be invited to participate in this study regardless of gender,&#xD;
        sex, race, or religion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients willing to participate and provide an informed consent.&#xD;
&#xD;
          -  Patients undergoing elective surgical procedures that require use of NMBA agents&#xD;
             (rocuronium) administered intraoperatively.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with&#xD;
             nerve damage, Dupuytren contracture, or any similar wrist injury.&#xD;
&#xD;
          -  Patients with systemic neuromuscular diseases such as myasthenia gravis.&#xD;
&#xD;
          -  Patients with significant organ dysfunction that can significantly affect&#xD;
             pharmacokinetics of neuromuscular blocking and reversal agents; i.e., severe renal&#xD;
             impairment or end-stage liver disease.&#xD;
&#xD;
          -  Patients having surgery that would involve prepping the arm into the sterile field.&#xD;
&#xD;
          -  Patients receiving a rapid sequence induction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Ross Renew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>J. Ross Renew, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>neuromuscular blockade</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

